open access

Vol 65, No 1 (2015)
Review paper
Published online: 2015-03-06
Get Citation

Immunomodulatory antibodies in cancer therapy

Michał Marciniec, Andrzej Nowak, Agata Filip
DOI: 10.5603/NJO.2015.0005
·
Nowotwory. Journal of Oncology 2015;65(1):42-47.

open access

Vol 65, No 1 (2015)
Review article
Published online: 2015-03-06

Abstract

Among the immunomodulatory drugs modifying the immune system are monoclonal antibodies. Negative recep­tors, such as Cytotoxic T Cell Antigen 4 (CTLA-4) and Programmed Cell Death protein 1 (PD-1), reduce the level of cell stimulation by other receptors in the cases described. They inhibit the activation and proliferation of T cells. The physiological function of these receptors is the elimination of autoreactive immune cells, which have not been destroyed in the mechanism of central tolerance, and the protection of inflamed tissues in the body. Tumours by expressing negative receptor ligands avoid recognition by the immune system. Antibodies action involves blocking CTLA-4 and PD-1 receptors, restoring the ability of lymphocytes to recognise and respond to tumour antigens. Previous studies of anti-CTLA, anti-PD-1 and anti-PD-L1 drugs are moderately effective in the treatment of some advanced cancers with durable remission of the tumour. It has been proved that it is particularly advantageous to combine the two agents in synergistic effect. Despite the encouraging results of previous studies, it is necessary to find objective markers for estimating the benefits of treatment, to reduce the amount of side effects and normalise the prices of new drugs.

Abstract

Among the immunomodulatory drugs modifying the immune system are monoclonal antibodies. Negative recep­tors, such as Cytotoxic T Cell Antigen 4 (CTLA-4) and Programmed Cell Death protein 1 (PD-1), reduce the level of cell stimulation by other receptors in the cases described. They inhibit the activation and proliferation of T cells. The physiological function of these receptors is the elimination of autoreactive immune cells, which have not been destroyed in the mechanism of central tolerance, and the protection of inflamed tissues in the body. Tumours by expressing negative receptor ligands avoid recognition by the immune system. Antibodies action involves blocking CTLA-4 and PD-1 receptors, restoring the ability of lymphocytes to recognise and respond to tumour antigens. Previous studies of anti-CTLA, anti-PD-1 and anti-PD-L1 drugs are moderately effective in the treatment of some advanced cancers with durable remission of the tumour. It has been proved that it is particularly advantageous to combine the two agents in synergistic effect. Despite the encouraging results of previous studies, it is necessary to find objective markers for estimating the benefits of treatment, to reduce the amount of side effects and normalise the prices of new drugs.

Get Citation
About this article
Title

Immunomodulatory antibodies in cancer therapy

Journal

Nowotwory. Journal of Oncology

Issue

Vol 65, No 1 (2015)

Article type

Review paper

Pages

42-47

Published online

2015-03-06

DOI

10.5603/NJO.2015.0005

Bibliographic record

Nowotwory. Journal of Oncology 2015;65(1):42-47.

Authors

Michał Marciniec
Andrzej Nowak
Agata Filip

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl